System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Eicke Latz is an expert in Immunology at University Hospital Bonn (Germany). Eicke Latz has authored 434 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 1,925 (community average: 125). How the SLR is computed.

LeadR Profile

Eicke Latz University Hospital Bonn Germany
1 925 ScienceLeadR Reputation 1925

Unlock

Register Login
Network Map

Immunology

Subspecialties: Neurology - Endocrinology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

University of Bonn

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 434

Citations

Citations: 89 329 1st author: 10 Last author: 87 Unique author: 18

Main journals

J Immunol 28
Nat Immunol 27
Immunity 15
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 14
J Biol Chem 13

Best Journals

Nature 12
Nat Rev Immunol 6
Cell 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts.
PMID 42951953 — arthritis, psoriatic, arthritis, rheumatic diseases, therapeutics		Nature Top journal20260
CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.
PMID 42661098 — cells, safety, arthritis, arthritis, rheumatoid, therapeutics, t-lymphocytes, b-lymphocytes, car-t cell		Nat Med Top journal20262
Author Correction: Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP.
PMID 42601481 — cells, immunity		Nature Top journal20260
Glucagon and beta-cell function changes before and after dietary weight loss-induced metabolic improvements in type 2 diabetes.
PMID 42341884 — diabetes mellitus, cells, fasting, insulin, diet, weight loss, glucagon, diabetes mellitus, type 2		Diabetes Res Clin Pract20260
Targeting Inflammation by Pioglitazone and its R-Enantiomer Mitigates Pathological Myocardial Remodeling in Murine Hypertrophic Cardiomyopathy.
PMID 42287760 — cardiomyopathy, hypertrophic, pioglitazone, cardiomyopathies		JACC Basic Transl Sci20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Director: 1

By phase:

N/A 4
Phase 1/Phase 2 1

By status:

Completed 2
Unknown 2
Active not recruiting 1

By type:

Observational 3
Interventional 2

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Comparison of B cell Depletion by Rituximab and Anti CD 19 CAR T Therapy in Patients With Rheumatoid Arthritis
NCT06475495 — cells, safety, arthritis, immunotherapy, rituximab, antibodies, monoclonal, arthritis, rheumatoid, therapeutics, t-lymphocytes, b-lymphocytes, car-t cell		Phase 1/Phase 2Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS